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ABSTRACT
Omi/HtrA2 is a mitochondrial serine protease with a dual and opposite function
depending on its subcellular localization. Most of the previous studies focused on
Omi/HtrA2’s pro-apoptotic function when the protein is released to the cytoplasm. It is
becoming apparent that the main function of Omi/HtrA2 is within the mitochondria,
where it has a pro-survival role. However, its mechanism is still poorly understood. To
this end, we used the yeast two-hybrid system to dissect the Omi/HtrA2 pathway by
identifying novel interactors and substrates. Our studies revealed a novel function of
Omi/HtrA2 in the regulation of a deubiquitinating (DUB) complex. In addition we found
that Omi/HtrA2 participates in mitophagy by regulating Mulan E3 ubiquitin ligase, which
recruits GABARAP (gamma-amino-butyric acid receptor-associated protein) to the
mitochondria.
Abro1 is the scaffold protein of the DUB complex known as BRISC (BRCC36
isopeptidase complex) that is specific for Lys-63 deubiquitination. This complex is
similar to the BRCA-1 complex, a known and important player in DNA damage
response. Using the yeast two-hybrid screen and a bait consisting of the unique
carboxy-terminus of the Abro1 protein, we identified three transcription factors which are
members of the activating protein 1 (AP-1) family, namely ATF4, ATF5 and JunD. The
AP-1 family member ATF4 is ubiquitously expressed, like Abro1, and important in cell
cycle regulation and survival, thus we further analyzed this interaction.

Abro1’s

interaction with ATF4 was specific and present only when cells are under cellular stress.
When Abro1 protein level is increased it provides protection against stress-induced cell
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death, but interaction between Abro1 and ATF4 is necessary to achieve this protection.
The significance of this interaction was the translocation of Abro1 from the cytoplasm to
the nucleus. These results establish a new cytoprotective function of cytoplasmic
Omi/HtrA2 as a regulator of the BRISC DUB complex.
Under normal conditions Omi/HtrA2 is localized in the intermembrane space
(IMS) of the mitochondria. We have recently identified that the mitochondrial Mulan E3
ubiquitin

ligase

is

a

substrate

of

Omi/HtrA2

protease.

Mulan,

along

with

MARCH5/MITOL and RNF185, are the only three mitochondrial E3 ubiquitin ligases
identified thus far. The function of Mulan has been linked to cell growth, cell death and
autophagy/mitophagy. In addition, we showed that Omi/HtrA2, through regulation of the
Mulan protein level, controls mitophagy, especially during mitochondrial stress. To
understand Mulan’s function and its control by Omi/HtrA2, we set out to identify E2
conjugating enzymes that form a complex with Mulan E3 ligase. We isolated four
specific interacting E2’s, namely Ube2E2, Ube2E3, Ube2G2 and Ube2L3. To identify
substrates for each unique Mulan-E2 complex we used fusion baits in a second yeast
two-hybrid screening. One of the interactors isolated against the Mulan-Ube2E3 bait
was the GABARAP protein, a member of the Atg8 (autophagy) family. The mammalian
Atg8 family is composed of seven members that have been linked to important roles in
autophagy/mitophagy. We characterized this interaction both in vitro and in vivo and its
role in mitophagy. Our results suggest that Mulan participates in various pathways,
depending on the nature of its partner E2 conjugating enzyme. In addition, we identified
the pathway by which Mulan participates in mitophagy by recruiting GABARAP to the
mitochondria.
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CHAPTER 1: INTRODUCTION
Protein homeostasis is essential for a cell’s ability to survive and thrive. This
process requires precise control of protein synthesis, processing, and protein
degradation. Misfolded and damaged proteins are processed through protein quality
control (PQC) mechanisms, in which the proteins are degraded through the ubiquitin
proteasome system (UPS) or autophagy.
Since its first discovery in the late 1970s, ubiquitin has gained much attention as
a marker for protein destruction, but it has been noted recently that ubiquitin also plays
a role in other physiological functions (1). Some of the cellular processes in which
ubiquitin has been linked to include: antigen processing, apoptosis, biogenesis of
organelles, cell cycle and division, DNA transcription and repair, differentiation and
development,

immune

response

and

inflammation,

neuronal

and

muscular

degeneration, morphogenesis of neural networks, modulation of cell surface receptors,
the secretory pathway, response to stress and extracellular modulators, ribosome
biogenesis and viral infection (for current reviews see (1-4)). Dysfunction of
ubiquitination is implicated in multiple pathological conditions and human diseases.
Disorders involving UPS dysfunction include Alzheimer’s disease, Parkinson’s disease,
Huntington’s disease, prion-like lethal disorders, cystic fibrosis, cancer and many more
(2, 5-8).
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Apoptosis
Apoptosis is a process whereby the cell decides to “commit suicide”. There are
two pathways of apoptosis: the intrinsic pathway and the extrinsic pathway (Figure 1)
(9). The extrinsic pathway involves transmembrane receptor-mediated interactions that
include members of the tumor necrosis factor (TNF) receptor gene superfamily (10).
Members of the TNF family contain a cysteine-rich extracellular domain as well as a
cytoplasmic domain, called the death domain (DD), which plays an important role in
transmitting the information from the cell surface to intracellular pathways (11). The best
characterized models of the extrinsic apoptotic pathway are the FasL/FasR and TNFα/TNFR1 models, in which there is a clustering of receptors that binds to the trimeric
ligand. Cytoplasmic adapter proteins with corresponding DDs are then recruited to the
receptors. In the FasL/FasR model, the adapter protein is FADD (12-14). FADD will
then interact with procaspase-8 (the inactive form of caspase-8) through dimerization of
the death effector domain (DED), forming a complex collectively known as the deathinducing signal complex (DISC). DISC can then in turn activate more procaspase-8,
thus leading to the triggering of apoptosis (15).
On the other hand, the intrinsic pathway initiates apoptosis by intracellular
signals that do not derive from receptor-mediated stimuli. Instead, the signals come
from within the cell and are mitochondrial-initiated events which can be either positive or
negative signals. Negative signaling involves the absence of certain growth factors,
cytokines or hormones that when withdrawn, the suppression of apoptosis is lost (16).
Positive signaling are stimuli that when present lead to apoptosis; examples include
radiation, toxins, and free radicals (16). Both positive and negative stimuli cause a loss
2

in mitochondrial transmembrane potential through the opening of mitochondrial
permeability transition (MPT) pores in the inner mitochondrial membrane. With the
opening of these pores there is also the release of pro-apoptotic proteins from the
intermembrane space (IMS) which can be divided into two subgroups (17). The first
subgroup includes the proteins cytochrome c, Smac/DIABLO and Omi/HtrA2 which can
activate the caspase-dependent mitochondrial pathway of apoptosis (18-20). The
cytochrome c achieves this by binding and activating Apaf-1 and procaspase-9, which
collectively form the apoptosome (21, 22). Smac/DIABLO and Omi/HtrA2 promote
apoptosis by inhibiting the inhibitors of apoptosis proteins (IAP) activity (19, 23). The
second subgroup includes AIF, endonuclease G and CAD which are also released from
the mitochondria later and only after the cell has committed to death (24).
The control and regulation of the mitochondrial apoptotic events are orchestrated
by the Bcl-2 family of proteins (25). These proteins are in charge of the mitochondrial
membrane permeability and can play a role as either pro-apoptotic or anti-apoptotic.
There is also cross-talk between the two pathways, for example, mitochondrial damage
in the Fas pathway is mediated through the cleavage of Bid by caspase-8 (26-28).
Activation of the execution pathway occurs when both the intrinsic and extrinsic
pathways end and is considered the last step of the apoptotic pathway. Execution
caspases (caspase-3, caspase-6, and caspase-7) are activated and begin the final
steps of apoptosis by cleaving various substrates such as PARP and plasma membrane
cytoskeletal proteins (29). The most important execution caspases is caspase-3, which
can be activated by any of the initiator caspases that are part of the intrinsic or extrinsic
pathways, which include caspase-8, caspase-9 or caspase-10. The activated caspase-3
3

cleaves ICAD which is normally bound to the endonuclease CAD, inhibiting its function
(30). Activated CAD will then degrade the chromosomal DNA, causing chromatin
condensation, as well as cytoskeletal reorganization. The last step of apoptosis is
phagocytic uptake of the apoptotic cell, which includes the translocation of
phosphatidylserine to the outer leaflet of the cell.

Omi/HtrA2
Omi/HtrA2 is a serine protease and a member of the HtrA family in Eukaryotes
(31). Along with Omi/HtrA2, there are also HtrA1/L56 and HtrA3/PRSP, which are all
homologous to the bacterial HtrA endoprotease, a proteolytic enzyme that removes
damaged and denatured proteins at elevated temperatures (32). Omi/HtrA2 is
synthesized as a precursor at 458 amino acids and is processed in the mitochondria to
its mature form through the removal of the first 133 amino acids, exposing a AVPS motif
(33). Unlike the other members of the HtrA family, Omi/HtrA2 is not secreted and it is
exclusively located in the IMS of the mitochondria under normal conditions (31, 34, 35).
Omi/HtrA2, like the rest of HtrA proteins, contains a catalytic domain as well as a PDZ
domain (postsynaptic disk large and zonula occludens 1) known to be involved in
protein-protein interaction (Figure 2) (32).
After its release to the cytoplasm, Omi/HtrA2 binds and degrades several
proteins including the X chromosome-linked inhibitor of apoptosis protein (XIAP) which
results in the activation of caspase-9 (31). Omi/HtrA2 can also induce apoptosis in a
caspase-independent manner but the mechanism of this function remains unknown (3639). A surprising and unexpected new function of Omi/HtrA2 was uncovered when it
4

was found that its inactivation is responsible for the mnd2 (motor neuron degeneration)
phenotype in mice.

These animals carry a spontaneous mutation on Ser276Cys

located in the protease domain, and homozygous animals exhibit muscle wasting,
neurodegeneration, involution of the spleen and thymus, and a shortened life span,
typically dying by 40 days of age (40-42). Mutations in the HtrA2 gene have also been
linked to Parkinson’s disease although these data were contradicted by later studies
(43, 44). Another study has recently linked Omi/HtrA2 and the prevention of lymphocyte
apoptosis through the suppression of activated Bax (45).
The phenotype of Omi/HtrA2 KO animals suggests that this protease has two
different and opposite functions based on its subcellular location. In the mitochondria,
Omi/HtrA2 has a cytoprotective function; whereas once it is released to the cytoplasm, it
has a pro-apoptotic role. Most of the studies so far have focused on its pro-apoptotic
function and very little if anything is known about what it does in the mitochondria. Its
bacterial homologue DegP is a molecular chaperone under low temperatures which
helps fold proteins and assemble oligomers, but in high temperature environments, it
acts as a protease (33). Since DegP acts as a chaperone, it has been assumed that
Omi/HtrA2 has some sort of similar function while in the mitochondria.

Thus far,

Omi/HtrA2 has been found to interact and cleave HAX-1, WARTS, Ped/Pea-15, XIAP,
cIAP1, cIAP2, APP, THAP5, HSPA8, amyloid-β protein and WT1 (46-56). There has
also been contradicting information regarding the functional interaction between
Omi/HtrA2 and parkin or PINK1 (57, 58).
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Ubiquitination
Ubiquitin (Ub) is a small 76 amino-acid, 8kDa, peptide that can be covalently
attached via the carboxyl group of its carboxy-terminus residue (Gly76) to a lysine in the
substrate (59, 60). Ubiquitination of a target protein occurs through sequential reactions
involving three classes of enzymes: ubiquitin-activating (E1), ubiquitin-conjugating (E2)
and ubiquitin-ligase (E3) enzymes (Figure 3) (61). The E1 activates the ubiquitin peptide
by forming a high energy thioester bond between a cysteine in the E1’s active site and
the carboxy-terminus of the ubiquitin via the hydrolysis of one ATP molecule. The active
ubiquitin is then transferred to an E2 through the formation of a new thioester bond.
Finally, the ubiquitin is directly or indirectly transferred to the target protein’s ε-amino
group of a lysine (5). The addition process can happen once (monoubiquitination) or
repeatedly, forming a poly-ubiquitin chain where each additional ubiquitin is linked to
one of the seven Lysines (K or Lys) - K6, K11, K27, K29, K33, K48, and K63 - present
in the terminal ubiquitin molecule (1). The fate of the target protein is dictated by the
length and the type of the Ub-chain formed; the most well understood and studied are
Lys-48 chains which are responsible for targeting proteins to the proteasome for
degradation (62).
There are two E1s, more than 30 E2s, and over 1000 E3s identified in the
Eukaryotes (63). E2 conjugating-enzymes are classified as Class I through IV, where
Class I E2s consist of only the catalytic domain; Class II and III have an extension at
either the amino- or carboxy-terminus, respectively, and Class IV have both extensions
(64). The E3s can be further divided into two major classes: HECT (homologous to E6AP carboxy-terminus) and RING (really interesting new gene) families. The HECT
6

ligases catalyze the formation of an ubiquitin-thioester intermediate, followed by the
transfer of the ubiquitin to the target protein (61). RING ligases do not form an
intermediate and instead function as a scaffold protein bringing the substrate and E2
into close proximity (65). Some reports also recognize a class of E4 enzymes,
specifically those of the U-box type, which are associated with the elongation of the
ubiquitin chain rather than the addition of the first ubiquitin (65). Proteins that are
ubiquitinated for destruction contain a “death domain” where the target lysine is
recognized by a specific heterodimer formed between the E2 and E3, creating great
substrate diversity (66). These domains can be hidden if the protein is correctly folded,
only appearing for interaction with the heterodimer if the folding is wrong, or it is present
at all times in short-lived proteins, such as those that play a role in the cell-cycle (67).
Once a protein is tagged for destruction via ubiquitination, it is transported to the
26S proteasome by shuttling factors; this process predominantly occurs in the cytosol
where the majority of the factors are present (5, 67). The 26S proteasome is assembled
from two 19S regulatory complexes (the lid and base) as well as a 20S central particle
(65). Protein degradation is not the only function of ubiquitination. One of the first
identified functions was its involvement in cargo internalization as well as cargo
targeting to specific vacuoles (68, 69). Another role of ubiquitination is sequestering of
the proteins to prevent their activity (70).
Due to the large number of possible target substrates of the UPS, it is no surprise
that this process is directly and indirectly involved in multiple pathways and that its
deregulation can be detrimental to the organism (5). Neurodegenerative diseases
caused by deregulation of the UPS include Alzheimer’s disease (AD), Parkinson’s
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disease (PD), amyotrophic laterial sclerosis (ALS), Huntington’s disease (HD),
spinocerebellar ataxias (SCAs) and Kennedy’s syndrome (5). Other disease states
include, but are not limited to, Cystic fibrosis (CF), autoinflammatory and autoimmune
diseases, prostate, breast, and colorectal cancer (5, 71-75).
There are also ubiquitin-like molecules (Ubls) which provide new protein-protein
interaction interfaces for protein recognition as well as for modifying their binding
affinities (76).

Deubiquitination
The opposite of ubiquitination is deubiquitination, the process in which the
covalently attached ubiquitin is removed or edited (77). As with ubiquitination,
deubiquitination is closely regulated. The human genome encodes for about 80
deubiquitinating enzymes (DUBs) that can be subdivided into five different families (78).
These families are: ubiquitin carboxy-terminal hydrolases (UCHs), ubiquitin-specific
proteases (USPs), ovarian tumor proteases (OTUs), Josephins (MJDs) and the
mettaloproteases JAB1/MPN/MOV34 (JAMMs) (76).
Removing the ubiquitin from the target protein plays an essential role in two
processes:

protein

degradation

by

biosynthesis/recycling (Figure 4) (65).

the

26S

proteasome

and

ubiquitin

Deubiquitinating enzymes are very tightly

regulated through their recruitment to the target proteins, chain specificity, and intrinsic
catalytic activity (79). Deubiquitination can assist in rescuing the substrate from
destruction as well as changing the protein’s location or activation state (80). Therefore,
this process is very important in many cellular functions, including regulation of receptor
8

trafficking,

cell

migration,

intracellular

signaling,

cell

cycle

progression

and

transcriptional control (81). Studying deubiqutinating enzymes and mechanisms is
therefore just as important as the ones involved in ubiquitinating.

Autophagy
Eukaryotic cells use two systems for protein degradation: the ubiquitinproteasome system (UPS) for short-lived and abnormal/misfolded proteins and the
autophagy-lysosome pathway for bulk degradation of long-lived proteins as well as
damaged organelles (82, 83). The word “autophagy” is derived from the Greek for “selfeating”, originally proposed over 40 years ago by Christian de Duve and can be
subdivided

into

three

categories

depending

on

its

cargo:

macroautophagy,

microautophagy and chaperone-mediated autophagy (CMA) (84, 85). When autophagy
is activated a pre-autophagosomal double membrane structure is created to surround
what is destined for degradation. The outer membrane then fuses with the lysosome to
form a single membrane vesicle called the autolysosome, where the inner membrane
and contents are degraded (Figure 5) (82). The pathway is important in many
physiological functions, such as cell development, cell death, pathogen infection, and
degradation of ubiquitinated proteins; any imbalance in this process is detrimental for
the cell and can lead to diseases such as cancer or Parkinson’s disease (86, 87). The
process was believed not to be selective, but recent studies have shown that there are
proteins that function to target ribosomes, lipid droplets, certain proteins, pathogenic
bacteria, and specific organelles for destruction (88-95). Autophagy differs from the
UPS system in that it doesn’t only eliminate single proteins, but it is just as selective
9

(96). Another belief that is no longer held to be true was that the UPS and autophagy
pathways were distinct, but new evidence shows that there is a cross-talk between the
two in which lack of autophagy leads to accumulation of ubiquitinated proteins. The
opposite is also true: when the preoteasome is inhibited, it leads to the activation of
autophagy, suggesting that the two pathways are indeed linked (97-99).
Autophagy has been linked to protein, lipid, and glycogen degradation (100). In
cells under starvation conditions, in which the amount of free amino acids for protein
synthesis has been compromised, there is an increase in autophagy that increases
amino acid turnover.
There is also evidence that ubiquitination is essential in the autophagy process.
Proteins, such as p62/SQSTM1 and NBR1, contain both an ubiquitin-associated (UBA)
domain as well as the WXXL motif called the LC3 interacting (LIR) domain, raising the
possibility that these proteins are working as adaptors in ubiquitination as well as
autophagy (94, 101). In addition, this link might be able to explain how autophagy can
be so specific.

Mitophagy
Mitochondria are the primary cellular site for energy production, apoptosis, Ca 2+
buffering and macromolecule synthesis; it also is the major source of reactive oxygen
species (ROS) that may oxidize their own lipids, proteins and DNA (102). Damaged
mitochondria release pro-apoptotic factors such as Omi/HtrA2 and cytochrome c which
lead to cell death through the intrinsic apoptotic pathway (103). By removing these
damaged mitochondria through mitophagy, the cell protects itself from apoptosis. In
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mammalian cells, mitophagy is preceded by mitochondrial fission to help break down
the mitochondria into more manageable pieces as well as for quality control segregation
(104). There appears to be two steps necessary for mitophagy to occur: activation of
the autophagic machinery followed by the selection of the dysfunctional mitochondria
(105-107). Mitophagy is not only present in cells under stress, but also in cell
differentiation. Erythrocytes do not have mitochondria or other organelles due to their
removal through mitophagy with the assistance of Nix (NIP3-like protein X, also known
as BNIP3-like protein (BNIPL3)) (108).
A recently identified pathway, and the only one thus far, requires the function of
PTEN-induced putative kinase protein 1 (PINK1) and the E3 ubiquitin ligase parkin
(109). To further validate their importance in mitophagy, the gene that encodes for
parkin has been shown to be mutated in Parkinson’s disease (110). Parkin is an E3
ubiquitin ligase which is expressed in many tissues suggesting widespread
physiological function, however, its deregulation is linked to neuronal loss in substantia
nigra (111). During cellular stress, parkin translocates from the cytosol to the
mitochondria. The same accumulation of parkin is seen when cells lose their ability to
fuse or lose mitochondrial potential, but this does not occur in healthy cells. If the stress
is prolonged, mitophagy is seen (88). With this information, it was hypothesized that
parkin mediates mitochondrial quality control. The recruitment of parkin to the
mitochondria is mediated by the activity of PINK1 (Figure 6) (111-117).
PINK1 translocates and is rapidly degraded in healthy mitochondrion; however,
accumulation of PINK1 is seen in injured/damaged cells, indicating a mechanism for
sensing mitochondrial damage (111). When the mitochondrion is damaged, there is a
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halt in PINK1 destruction, which leads to the accumulation of the protein and the
recruitment of Parkin specifically (111, 116, 118). The mechanism which degrades
PINK1 or how its accumulation leads to the recruitment of parkin is still unclear.
The E3 ubiquitin ligase activity of parkin increases when it is translocated to the
mitochondrion, which is believed to play an important role in the ubiquitylation of
mitochondrial substrates, one known substrate being the voltage-dependent anion
channel 1 (VDAC1) (88, 116). Using the uncoupling agent carbonyl cyanide mchlorophenyl hidrazone (CCCP) to induce mitophagy, leads to an increase in the Lys63linked chains in the outer mitochondrial membrane, an event normally associated with
signaling and not proteasomal degradation (115, 116, 119, 120). The ubiquitinated
proteins then interact with ubiquitin-binding adaptor proteins, such as p62, which then
can interact with the autophagosomal protein LC3 (101, 105).
Another substrate of parkin that is relevant to mitophagy is mitofusin, which when
degraded can inhibit re-fusion of mitochondria. We have also recently shown that
mitofusin is a substrate of Mulan (121-123). Atg8 is a family of proteins composed of
LC3, GATE-16/GABARAP, all of which have been shown to be critical in the maturation
of the autophagosome by interacting with phosphatidylethanolamine on the autophagic
membrane at different time points. While LC3 is important in the elongation of the
phagophore membrane, both GATE-16 and GABARAP are essential in a later stage of
maturation (124).
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Figure 1. Schematic representation of the two major apoptotic pathways: intrinsic and
extrinsic.
There are different signals needed to activate each of the two pathways, a cascade of molecular
events follows leading to apoptosis. Mitochondria permeability transition (MPT).
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Figure 2. Domain organization of HtrA family members.
Full-length Omi/HtrA2 consists of 458 amino acids serine protease located in the intermembrane space (IMS) of the mitochondria. The mature form of Omi/HtrA2 lacks the first 133
amino acids. The mature form contains a Trypsin-like proteasome domain as well as a PDZ
domain. The protease domain is composed of two six-stranded beta-barrels and the active site
contains the amino acid triad His-Asp-Ser. Both domains have been shown to be important in
Omi/HtrA2’s function.
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Figure 3. Protein ubiquitination.
The process of ubiquitination is achieved by three enzymes: activating ubiquitin enzyme (E1),
conjugating ubiquitin enzyme (E3) and ligase ubiquitin enzyme (E3). While there is a single E1,
there are many E2s and several E3s. The activation of ubiquitin occurs through a thioester bond
formation which requires ATP. The ubiquitin when attached to E2 can be directly transferred to
a substrate when they are brought closer together by the E3 (as seen with the RING family) or it
must first be transferred to the E3 itself (HECT family). The number and type of ubiquitin chain
varies and determines the fate of the substrate.
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Figure 4. Function of the deubiquitinating enzymes.
Deubiquitinating enzymes (DUBs) play many different roles to keep the cell in balance. (A)
Ubiquitin (Ub) is encoded as transcribed and translated as a linear fusion, consisting of multiple
subunits. DUBs will process this chain into free Ubs that can then be used. (B) When a protein
is Lys-48 polyubiquitinated for degradation it is translocated to the 26S proteasome in the
cytoplasm. Other chains, such as Lys-63, act as non-degradative signaling that can change a
protein’s function or location. These processes can be stopped and reversed by the removal of
the targeting chain by the DUB. (C) Before the protein is tagged for destruction, the chain is
removed by a DUB. This is important in keeping a balance in free Ub present in the cell. (D)
Different chains and different number of Ubs have different function. Some DUBs can edit the
chains, therefore changing the protein’s final outcome.

16

Figure 5. Protein quality control.
Nascent proteins must be folded to their final tertiary structure, and this can be achieved with
the help of chaperones. When native proteins are misfolded or unfolded the chaperones can
refold them, but if the chaperons are overwhelmed or cannot do this task, the proteins can
become aggregates or are tagged for destruction by the ubiquitin-proteasome system (UPS).
Protein aggregates are degraded by a process known as macroautophagy which is initiated by
adaptor proteins, followed by the formation of the autophagosome and which is then delivered
to the lysosome.
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Figure 6. Current model of mitophagy.
Currently there are two proposed pathways for mitophagy: the E3 ligase parkin is recruited to
the mitochondrion by PINK1, which is accumulated in mitochondria under stress. The ligase
then ubiquitinates its substrates, one of which is believed to be VDAC1, followed by the
recruitment of the adaptor protein p62. The adaptor protein then binds to the ubiquitin chain and
through its LIR domain it interacts with LC3 in the phagophore. The phagophore closes and
matures into the autophagosome. The second pathway involves Nix, a mitochondrial protein
found in the outer mitochondrial membrane (OMM) that contains an LIR sequence. By being
embedded in the mitochondria, Nix bypasses the need for substrate ubiquitination and it can
directly target the mitochondrion to the autophagosome.
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CHAPTER 2: ATF4 INTERACTS WITH ABRO1/KIAA0157
SCAFFOLD PROTEIN AND PARTICIPATES IN A CYTOPROTECTIVE
PATHWAY
As previously published in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Volume 1823, Issue 12, December 2012, Pages 2149–2156

Introduction
Our studies are focused on Abro1, which is the scaffold protein of the BRISC
deubiquitinating enzyme (DUB) complex, and its potential regulation through specific
protein-protein interactions during cellular stress.

Abro1 shares 39% similarity with

another protein, Abraxas, which is a scaffold protein for the BRCA1-A (breast cancer 1)
DUB complex (125).
BRE/BRCC45

and

Both complexes share three subunits: MERIT40/NBA1,
BRCC36/BRCC3,

a

member

(JAB1/MPN/Mov34) DUB metalloproteases (77, 126-129).

of

the

JAMM/MPN+

The similarity between

Abro1 and Abraxas is present at the amino-terminus and this part of the protein
interacts with the common subunits. We therefore assume that the distinct function of
the BRCA1-A and BRISC complexes is conferred by the unique carboxy-termini of
these proteins. Abraxas’ carboxy-terminus interacts with BRCA1, which targets the
BRCA1-A complex to specific DNA damage foci while the function of the Abro1
carboxy-terminus domain is unknown (125, 127, 130-132). Our previous studies have
shown that this domain can interact with a human cardiospecific transcription factor,
THAP5 (thanatos associated protein 5) (47). THAP5 is predominantly expressed in the
human heart whereas Abro1 is expressed ubiquitously, suggesting the existence of
other as yet unidentified proteins that interact with the unique carboxy-terminus of Abro1
and affect its function.

Furthermore, there is a disproportional number of subunits
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between the better characterized BRCA1-A complex consisting of six subunits and the
BRISC complex consists of only four subunits. This is in spite of the fact that both
scaffold proteins, Abro1 and Abraxas, are similar and comparable in size (126, 127).
In the present study, we used the yeast two-hybrid system to isolate proteins that
interact with the unique carboxy-terminus of Abro1. We screened a mouse embryonic
cDNA library that provides a broad representation of various tissue specific mRNAs.
We isolated JunD, ATF4 and ATF5 as specific interactors. These interactors are all
distinct members of the AP-1 family of transcription factors (133). They carry a basicleucine zipper motif at their carboxy-terminus and our studies show this domain to
interact with Abro1. We selected ATF4 for more detailed studies since this protein is
expressed ubiquitously and it has previously been shown to be a stress modulator with
an important function in heart disease (134, 135). Our results clearly show that Abro1
and ATF4 interact both in vitro as well as in vivo and this interaction is observed
predominantly in the cell nucleus. Furthermore, during ER stress the protein level of
ATF4 dramatically increases leading to a concurrent up-regulation of the ATF4-Abro1
complex.

Our previous studies show that Abro1 provides cytoprotection against

oxidative stress-induced cell death (136). We now demonstrate that ATF4 is necessary
for this function of Abro1, since reducing the ATF4 protein level significantly impairs its
anti-apoptotic role. Finally, our results suggest that Abro1 can be involved in multiple
specific interactions with various transcription factors. These interactions can either be
tissue specific or in response to a particular stress. The potential function of these
interactions could be the translocation of Abro1 scaffold protein and the BRISC complex
to various subcellular compartments including the cell nucleus. This in turn potentially
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allows the BRISC DUB complex to act on specific local Lys63-linked polyubiquitinated
substrates leading to cytoprotection.

Materials and Methods
Yeast two-hybrid screen
The EGY 48 yeast strain with the LexA-β galactosidase reporter construct (PSH
18-34) was used to perform a yeast two-hybrid screen on a mouse embryonic cDNA
library as previously described (32, 46, 47). The bait used was the unique carboxyterminus sequence of the Abro1 protein (amino acids 199-415) cloned in the pGilda
vector (Clontech) and expressed as a LexA fusion protein. Several interacting proteins
were identified in this screen, including a full-length cDNA for JunD and partial cDNAs
for ATF4 and ATF5 (a complete list of the interactors found is summarized in Table 1).
The full-length cDNAs for ATF4 and ATF5 were isolated from the mouse embryonic
cDNA library using the following specific primers:
mouse ATF4 full length:
Fw 5’-GCTTCGAATTCATGACCGAGATGAGCTTCCTG -3’,
Rw 5’-CACCGCT CGAGTTACGGAACTCTCTTCTTCCCCC-3’;
mouse ATF5 full length:
Fw 5’-GCTTCGAATTCATGTCACTCCTGGCGACCC-3’,
Rw 5’-CACCGCTCGAGCTAGGTGCTGCGGGTCCTC -3’.
For the bZIP constructs of ATF4, ATF5, JunD, fosB and Maf the following
primers with EcoRI and XhoI restriction sites were used:
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mATF4 aa280:
Fw 5’-GCTCGAATTCGACCCACCTGGAGTTAGTTTG-3’;
mATF5 aa195:
Fw 5’-GCTTCGAATTCCCCGCCCGCCCAGCCCCTTATC-3’;
mJunD aa241:
Fw 5’-GCTTCGAATTCCCGGACGTGCCGAGCTTCGGC-3’;
mfosB aa121:
Fw 5’-CCGGAATTCGGTGGGCCTTCAACCAGCAC-3’,
Rw 5’-CTGCTCGAGTTATGGCAAATCTCTCACCTCGC-3’;
mMaf aa286:
Fw 5’-CCGGAATTCATGTCGGTGCGCGAGCTGAAC-3’,
Rw 5’-CTGCTCGAGCTACCGTTTTCTCGGAA GCCGTTG-3’.
Primers were designed with an EcoRI site at the 5’ end and XhoI site at the 3’
end. PCR products were digested and cloned in frame into the prey pJG4-5 vector as
previously described (46). The presence and stability of the recombinant proteins in
yeast cells was monitored by Western blot analysis using LexA-antibodies (for baits) or
HA-antibodies (for preys).

Cell culture
HEK293T cells were grown in DMEM supplemented with 10% fetal calf serum
(Atlanta Biologicals), 2mM L-glutamine, 1.5g/l sodium bicarbonate, 1mM sodium
pyruvate, 50U/ml penicillin, and 50µg/ml streptomycin (Invitrogen) at 37°C and 5% CO2.

22

Interaction between Abro1 and ATF4 proteins in HEK293T cells
HEK293T cells were plated in 100mm dishes and transfected with 8.0µg of either
EGFP-Abro11-415 plasmid or pEGFP-C1 empty vector (Clontech) using Lipofectamine
2000 reagent according to the manufacturer’s instructions (Invitrogen). Fourteen hours
after transfection, half of the cells were treated with 20µg/ml of tunicamycin for 10 hours
and the other half were used as control (untreated). Cell lysates were prepared in RIPA
buffer (150mM NaCl, 50mM Tris-HCl pH 7.5, 1% NP-40, 0.25% sodium deoxycholate)
containing the protease-inhibitor cocktail (Roche).

The lysates were cleared by

centrifugation for 10 min at 10000g, and total lysates were collected and subjected to
immunoprecipitation. Approximately 200µg of total protein cell lysate was pre-cleared
by mixing with protein G-Agarose beads (Roche) for 1 hour followed by incubation with
ATF4 (Santa Cruz Biotechnology) or Abro1 (Bethyl) polyclonal antibodies for 2 hours at
4C. Protein G-Agarose beads were then added and allowed to bind overnight at 4C.
Immunoprecipitates were collected by brief centrifugation for 3 min at 800g and washed
three times with 500µl RIPA buffer. After the final wash, 25µl of RIPA buffer and 25µl of
2X SDS-PAGE sample buffer were added. All procedures were performed at 4°C.
Samples were boiled for 5 min and resolved by SDS-PAGE.

Proteins were then

electro-transferred onto a PVDF membrane and probed with either a mouse monoclonal
GFP (Santa Cruz Biotechnology) or a rabbit ATF4 antibody followed by a goat antimouse or Rabbit TrueBlot (eBiosciences) HRP-conjugated secondary-antibodies. The
immunocomplex was visualized using a SuperSignal West Pico Chemiluminescent
Substrate (Pierce).
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Sub-cellular localization of Abro1 and ATF4 proteins
To investigate the sub-cellular localization of Abro1 protein in the presence or
absence of ATF4, the cDNA encoding the full length Abro1 protein was cloned into
pEGFP-C1 vector (Clontech) and the cDNA for the full length ATF4 protein was also
cloned into the mRFP-C1 vector (Clontech). HEK293T cells were grown on glass cover
slips to 70% confluence and they were then transfected with 1µg of EGFP-Abro1 and
mRFP-ATF4 constructs using Lipofectamine 2000 Transfection reagent. Half of the
transfected cells were treated with 20µg/ml tunicamycin for 10 hours and the other half
used as control.

Both control and treated cells were washed and fixed in 4%

paraformaldehyde (PFA), permeabilized with 0.2% Triton X-100 and incubated in room
temperature with DAPI (Molecular Probes) in order to stain the nucleus. The cover slips
were then washed and placed on microscope slides using Fluoromount-G as the
mounting solution. Slides were observed using a Leica TCS SP5 II confocal laserscanning microscope (Leica). The expression and stability of the GFP-Abro1 and RFPATF4 proteins was verified by Western blot analysis using ATF4 or Abro1 specific
antibodies. For subcellular fractionation, HEK293 cells were grown to 80% confluence
and they were either left untreated (control), treated with 20µg/ml tunicamycin or 0.2mM
H2O2 for 10 hours. Cells were then collected and nuclear/cytoplasmic fractionation was
carried out using the NE-PER Nuclear and Cytoplasmic Extraction Reagents (THERMO
Scientific) according to the manufacturer’s protocol. A total of 40µg of protein from each
corresponding fraction was resolved by SDS-PAGE and analyzed by Western blotting
using ATF4, Abro1, β-Actin and Histone H1 specific antibodies.
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Regulation of Abro1 and ATF4 proteins by tunicamycin
HEK293T cells were plated in 60mm dishes and when they reached 90%
confluence they were treated with various concentrations of tunicamycin (0, 2.5, 5, 10,
20 and 50µg/ml) for 10 hours. Total cell lysates were prepared as described above and
40µg of protein was resolved by SDS-PAGE and analyzed by Western blotting using
ATF4 or Abro1 specific antibodies.

Inhibiting ATF4 protein level and Annexin V assay
HEK293T cells grown in 35mm dishes were co-transfected with 2.0µg pEGFP-C1
empty vector or pEGFP-Abro1 plasmid together with siRNA specific for ATF4 (siATF4)
siGENOME SMARTpool or scrambled siRNA (siCON) (Thermo Scientifc). Some of the
transfected cells were treated with 0.2mM of H2O2 for 10 hours. The percentage of
apoptotic cells in the transfected population was estimated by staining with
phycoerythrin-conjugated Annexin V at room temperature for 15 min in 1X binding
buffer followed by analysis on a FACSCalibur flow cytometer (47, 136). Cells were also
used to prepare cell lysates for Western blot analysis using ATF4 and Abro1 specific
antibodies.

Results
Isolation and characterization of Abro1 specific interactors
We employed a yeast two-hybrid system to isolate LexA-Abro1199-415 interactors.
We used a mouse embryonic cDNA library in order to screen as many diverse proteins
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as possible, including any tissue-specific interactors. Furthermore, using a cDNA library
constructed from primary cells avoids a potential problem often seen in cDNA libraries
prepared from transformed cell lines which often have deregulated expression of genes
involved in cell growth as well as cell death. The bait in this screen was the LexAAbro1199-415, which represents the coil-coil domain as well as the unique carboxyterminus of Abro1 protein that is completely different from its homologue, Abraxas
(Figure 7A).

The screen was performed as previously described (32, 46, 47).

Approximately one million independent yeast colonies were screened, one hundred
interactors were isolated and after further analysis several LexA-Abro1199-415 specific
interactors were identified (Table 1).

One of the specific interactors was a cDNA

encoding the full length JunD protein, while two other cDNAs represented partial
polypeptides of ATF4 (amino acids 21-349) and ATF5 (amino acids 20-283). All three
interactors are members of the AP-1 family of transcription factors (133).

Other

interactors included Ubiquitin C (UbC) and BRCC36. BRCC36 is a known interactor of
Abro1 and its isolation provides independent proof that the yeast two-hybrid screening
was successfully performed. Using specific primers and rapid amplification of cDNA
ends we were able to isolate the full-length cDNAs of ATF4 and ATF5, which were then
cloned back into the pJG4-5 vector and their interaction with LexA-Abro1199-415 was
verified. As with the partial polypeptides, full-length ATF4 and ATF5 proteins were able
to interact with LexA-Abro1199-415 in yeast (Figure 7B).

Figure 7C shows that all

constructs used in the experiments expressed the recombinant proteins in yeast.
ATF4, ATF5 and JunD are the only members of the large AP-1 family of proteins
that were isolated in our screen (133). They are distinct members but they all carry a
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similar bZIP domain at their carboxy-terminus (Figure 7D). To investigate the specificity
of the interaction between these three proteins and LexA-Abro1199-415, as well as to
investigate if the bZIP domain is involved in this specific intereraction, we chose two
other members of the AP-1 family as controls, namely fosB and Maf (137). ATF4, ATF5
and JunD share 59% similarity at the bZIP domain, whereas fosB and Maf are only 33%
similar (Figure 7D) (138). The bZIP domain of ATF4, ATF5 and JunD clearly interacted
with the unique carboxy-terminus of Abro1 equally well or even stronger than the fulllength proteins (Figure 7B). As predicted there was no detectable interaction between
LexA-Abro1199-415, and the bZIP domain of either fosB or Maf (Figure 7B).

Interaction of Abro1 with ATF4 in mammalian cells during stress
We focused our studies on ATF4 because this protein, like Abro1, is expressed
ubiquitously, known to be involved in generalized stress response and participates in
cardiovascular disease (139). To investigate whether Abro1 can interact with ATF4 in
vivo, in the presence or absence of cellular stress, HEK293T cells were transfected with
a construct encoding full-length Abro1 fused to GFP (GFP-Abro1) or empty pEGFP-C1
vector.

Tunicamycin was used to induce ER stress and twenty-four hours after

transfection total cell lysates were collected and a GFP antibody was used to precipitate
the GFP-Abro1 protein.

The presence of any ATF4 protein in the complex was

monitored by Western blot analysis using an ATF4-specific polyclonal antibody. Figure
8A shows that endogenous ATF4 interacts with GFP-Abro1 in HEK293T cells under
normal conditions as well as during ER stress. After tunicamycin treatment, another
form of the ATF4 polypeptide with a higher molecular weight also appears to associate
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with Abro1 (140). In addition, we performed the reverse experiment using the ATF4
antibody to precipitate endogenous ATF4 and any associated GFP-Abro1 protein.
Figure 8B clearly shows that endogenous ATF4 interacts with the GFP-Abro1 protein.
There was not any detectable interaction when GFP protein was expressed alone
(Figure 8A and B).

Subcellular localization of Abro1 and ATF4 proteins during stress
Abro1 is predominantly a cytoplasmic protein (127) while ATF4 is found both in
the nucleus and the cytoplasm (141). To better understand the biological role of the
ATF4-Abro1 interaction, HEK293T cells were co-transfected with GFP-Abro1 (amino
acids 1-415) and mRFP-ATF4 (amino acids 1-349). Using a Leica TCS SP5 II confocal
laser-scanning microscope we observed that in the absence of stress, GFP-Abro1 was
predominantly in the cytoplasm whereas mRFP-ATF4 was in the cell nucleus (Figure
8C, top panel). When transfected cells were treated with tunicamycin, some of the
GFP-Abro1 protein translocated to the nucleus where it co-localized with the mRFPATF4 protein (Figure 8C, bottom panel). In cells co-transfected with GFP-Abro1 and
empty mRFP, the GFP-Abro1 protein remained in the cytoplasm after tunicamycin
treatment (results not shown). To quantify these results, a total of 300 co-transfected
cells were counted between 15 fields of view for each control or following tunicamycin
treatment. The average of co-transfected cells with GFP-Abro1 in the cytoplasm was
60%, which decreased to 28% in cells treated with tunicamycin. Cells with GFP-Abro1
in the nucleus increased from 40% in the control to 72% in tunicamycin treated cells.
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To verify that the results are not due to the overexpression of these two
GFP/RFP-fusion polypeptides, we investigated the potential translocation and colocalization of endogenous Abro1 and ATF4 proteins.

For this experiment,

untransfected cells were treated with tunicamycin or H2O2 to induce cellular stress. The
cytoplasmic and nuclear fractions were isolated and analyzed by SDS-PAGE followed
by Western blot. Figure 8E shows that there was a small amount of Abro1 protein in the
cell nucleus of control untreated cells. This level of nuclear Abro1 protein increased in
cells treated with tunicamycin or H2O2. ATF4 was almost exclusively present in the cell
nucleus; H2O2 treatment increased ATF4 protein level while tunicamycin had a much
greater effect. Furthermore, the mobility of the ATF4 polypeptide in the SDS-PAGE gel
was slightly different in cells treated with tunicamycin or H2O2. This is probably due to
posttranslational modification suggesting tunicamycin and H2O2 could regulate ATF4
protein through different mechanisms.

Regulation of ATF4 and Abro1 protein levels by tunicamycin
Translocation of Abro1 to the nucleus seems to occurs when ATF4 protein is
overexpressed and at the same time cellular stress is induced.

Therefore we

investigated whether the endogenous level of ATF4 or Abro1 is regulated in cells
treated with various concentrations of tunicamycin. Figure 9A shows a progressive and
significant increase in the ATF4 protein level in cells treated with various concentrations
of tunicamycin. In contrast to ATF4, Abro1 protein level remained the same and was
not regulated by tunicamycin (Figure 9B).
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Abro1 induced cytoprotection requires the presence of ATF4 protein
Abro1 has been previously shown to have a cytoprotective role following
oxidative stress (136). To investigate if ATF4 is involved in this process we transfected
cells with GFP-Abro1 in the presence of ATF4 siRNA or scrambled control siRNA.
Under normal conditions the basal level of apoptosis in cells transfected with GFPvector alone was 12.5% versus 4% in cells transfected with GFP-Abro1 (Figure 10A).
When the cells were treated with H2O2, 71% of the cells transfected with GFP-vector
alone were apoptotic compared to 44% of cells transfected with GFP-Abro1. Inhibiting
the ATF4 protein level using siATF4 significantly reduced the Abro1 cytoprotective
ability and the number of apoptotic cells increased from 44% to 64% (Figure 10A).
These results clearly demonstrate that ATF4 is necessary and essential for the
cytoprotective function of Abro1 following oxidative stress. Figure 10B shows the ATF4
protein levels under the various conditions as well as the effect of siATF4. Furthermore,
induction of apoptosis by H2O2 in HEK293T cells does not affect the endogenous
protein levels of Abro1 (Figure 10C) and ATF4 (results not shown).

Discussion
Ubiquitination is a post-translational modification discovered in the 1980s that
has gained a lot of attention for its biological significance and its potential role in the
development of human disease (for a recent review see (142)). The modification is
through the addition of ubiquitin, a small 76 amino-acid protein of about 8.5kDa in size.
There are a total of eight different polyubiquitin linkages, and depending on the lysine
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used on the ubiquitin for attachment, the number of ubiquitins in a chain or type of chain
made, it can bestow a different fate to the substrate protein (143). Ubiquitination is
involved in diverse processes such as protein degradation, cell-cycle progression,
receptor transport, immune-response and viral infection (70, 144). The most common
and better-understood form of polyubiquitination involves the Lys48-linked chain.
Substrates that are Lys48-linked are known to be targeted for degradation by the 26S
proteasome (143). Another form of ubiquitination is Lys63-linked, which has a nonproteolytic role but regulates a protein’s function, its subcellular localization or proteinprotein interaction in response to cytoplasmic or nuclear cues (145). Ubiquitination can
be reversed by deubiquitination, which is mediated by DUBs.

There are over 100

putative DUBs identified in mammalian cells, subdivided into five-distinct families (78,
146).

As with ubiquitination, deubiquitination is also highly regulated, it has been

implicated in many cellular functions and its deregulation can lead to many human
diseases (78, 144, 146).
We have recently uncovered an important role for Lys63-ubiquitination as a
cytoprotective mechanism in the heart (136).

This mechanism is mediated by the

BRISC DUB complex, which contains a member of the JAMM/MPN+ family of DUBs,
BRCC36. Another complex that employs this JAMM/MPN+ DUB is BRCA1-A. The
BRCA1-A complex has been extensively studied and is found in the nucleus where it
interacts with histones and DNA to assist with double-stranded DNA damage repair
(125, 126, 132). Unlike the BRCA1-A complex, very little is known about the normal
function of the BRISC complex or its role in cellular stress. Both complexes rely on
similar scaffold proteins, Abro1 and Abraxas, to recruit the various polypeptides that
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make up the complex. The similarity of these two scaffold proteins is restricted to the
amino-terminus of the proteins, whereas their carboxy-terminus is quite distinct. The
BRCA1-A complex consists of the following polypeptides: RAP80, BRE, MERIT40,
Abraxas, BRCC36 as well as the BRCA1-BARD1 heterodimer. The BRISC complex is
made up of four subunit polypeptides: BRE, MERIT40, BRCC36 and Abro1. Three of
these subunits (BRE, BRCC36 and MERIT40) are common in both complexes and
interact with the similar amino-terminus domain of Abro1 and Abraxas. The unique
carboxy-terminus of Abraxas binds to RAP80 and the BRCA1-BARD1 heterodimer,
where the interaction is regulated by phosphorylation (125, 127). RAP80 allows the
complex to interact with ubiquitinated histones in DNA damage foci, while BRCA1BARD1 interaction helps localize the complex (131, 147). Abro1 has its own unique
carboxy-terminus and our recent studies have identified this domain to interact with the
human zinc finger protein THAP5 (47). THAP5 expression is highly restricted to the
heart and brain, and furthermore it has no mouse or rat homologue (47). Therefore, we
assumed that, besides THAP5, there might be other protein(s) that could interact with
Abro1 to modulate its activity or its subcellular localization. We used a yeast two-hybrid
screen to isolate and characterize Abro1 specific interactors from a mouse embryonic
cDNA library. From hundreds of potential interactors, we narrowed down our search to
only a few true protein-protein interactors. These included the JunD, ATF4 and ATF5
proteins that are members of the AP-1 family of transcription factors as well as the
BRCC36, a known component of the BRISC complex. JunD, ATF4 and ATF5 proteins
are known to form homo- and heterodimers that bind to specific DNA sites to regulate
the transcription of target genes (133).
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We focused our studies on the ATF4-Abro1 interaction because this transcription
factor is expressed ubiquitously (similarly to Abro1), it is known to be involved in cellular
stress and to potentially play a role in the development and progression of heart disease
(134, 135). The interaction of ATF4 with Abro1 was verified in yeast as well as in
mammalian cells. The carboxy-terminus of ATF4 was shown to be responsible for the
interaction with Abro1. This domain is known to carry the bZIP motif that is involved in
protein-protein and protein-DNA interactions (148). Furthermore, this motif is similar in
JunD and ATF5 proteins that were also isolated in our screen.

We verified the

specificity of this interaction by using two other members of the AP-1 family (fosB and
Maf) that have limited similarity at their bZIP motif with that of ATF4, ATF5 and JunD,
and because of this they were unable to interact with Abro1.

To investigate the

biological significance of the Abro1-ATF4 interaction in normal cells and during cellular
stress, cells were treated with tunicamycin (an ER stressor) and the subcellular
localization of these two proteins was observed. Under normal conditions Abro1 is
predominantly cytoplasmic and ATF4 is mostly nuclear but in the presence of
tunicamycin Abro1 is translocated into the nucleus where it co-localized with ATF4.
Since the translocation of Abro1 occurred when ATF4 was overexpressed and stress
was applied, we investigated whether the endogenous ATF4 protein level might be
regulated by tunicamycin. The ATF4 protein level was found to substantially increase
and be directly proportional to the concentration of tunicamycin used. Abro1, on the
other hand, did not respond to the tunicamycin treatment and its protein level remained
unchanged. Furthermore, tunicamycin treatment not only increased the ATF4 protein
level but also its post-translational modification. At higher tunicamycin concentrations
33

various forms of ATF4 with higher molecular weight appeared. We assume that these
represent polyubiquitinated forms of the polypeptide since it is known that ATF4 is
ubiquitinated and degraded by the proteasome (149, 150). The biological relevance of
the ATF4-Abro1 interaction was further investigated using a previously described assay
where overexpression of Abro1 protects cells from apoptosis induced by oxidative
stress (136). Oxidative stress also increases the amount of nuclear Abro1 protein. In
this assay, the cytoprotective effect of Abro1 was dramatically reduced when the ATF4
protein level was inhibited by siRNA. The interaction of Abro1 with ATF4, as well as
ATF5 and JunD, suggests that various nuclear proteins can bind to this scaffold protein
in the nucleus. These proteins could act as a “driver” for the Abro1 polypeptide in a
similar manner to the BRCA1-BARD1 interaction with Abraxas to direct the BRCA1-A
complex to the DNA damage foci (131). In addition, we cannot exclude the possibility
that the interaction of ATF4, ATF5 and JunD with Abro1 can also modulate the DUB
activity of the BRISC complex. Based on our data, as well as previously published
work, we were able to assign three discernible functional domains to the BRISC and
BRCA1-A complexes: (a) the scaffold domain, represented by Abro1 and Abraxas; (b)
the catalytic domain which includes the common polypeptides BRCC36, MERIT40 and
BRE; and (c) the “driver” domain which in BRCA1-A includes the BRCA1-BARD1
heterodimer and RAP80, and in BRISC it can include one of the following four
polypeptides: ATF4, ATF5, JunD and THAP5 (Figure 11). The presence of several
“driver” proteins that could interact with Abro1 at any time suggests that this process
could be further regulated. The identity of the “driver” proteins that interact with Abro1
could be determined by the particular tissue/cell line or the type and severity of the
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cellular stress. In addition, we have previously shown that the translocation of Abro1 to
the cell nucleus by THAP5 leads to the deubiquitination of specific substrates (136).
Our results suggest that either Abro1 translocation carries the complete BRISC complex
to the nucleus or the complex assembles soon after nuclear localization of Abro1. It will
be important to identify the Lys63-linked polyubiquitinated substrates of BRISC and to
investigate how their deubiquitination results in cytoprotection against oxidative stressinduced cell death.
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Table 1. A list of Abro1199-415 interactors isolated in our yeast two-hybrid screen using a
mouse embryonic cDNA library.

Abro1199-415 Interactors

Accession Number

Number of Independent Clones

ATF4

NM_009716.2

8

JunD

NM_010592.4

4

NM_001018055

4

ATF5

NM_030693.2

2

UbC

NM_019639

1

BRCC36
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Figure 7. ATF4, ATF5 and JunD interact with LexA-Abro1199-415 using their bZIP domain.
(A) A schematic representation of the Abraxas and Abro1 proteins showing their similar ABR
and coil-coil domains as well as their unique carboxy-termini. Abraxas contains three
phosphorylation sites (denoted by the *) that regulate its interaction with BRCA1-BARD1 which
are absent in Abro1 [1]. The unique carboxy-terminus of Abro1 (amino acids 199-415) fused to
LexA was used as the bait in the yeast two-hybrid screen. (B) Blue yeast colonies result from a
positive protein-protein interaction between the bait and prey. (C) Single yeast colonies were
grown overnight, induced with galactose/raffinose media the next day for four hours and then
used in a Western blot analysis to verify the expression and stability of the various recombinant
proteins in yeast. (D) Alignment of the amino acid sequences of the AP-1 family members used
in our experiments to illustrate the similarity in their bZIP domains. [MultAlin software
(http://multalin.toulouse.inra.fr/multalin)]
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Figure 8. Interaction and subcellular localization of Abro1 and ATF4 in mammalian cells.
(A) HEK293T cells were plated in duplicate and transfected with either GFP-vector or GFPAbro1. Twenty-four hours after transfection, one of the plates was treated with tunicamycin and
the other plate was used as control. GFP-specific antibody was used to precipitate GFP or
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GFP-Abro1. The immuno-complex was resolved on SDS-PAGE followed by Western blot
analysis and the presence of ATF4 in the precipitated complex was detected using ATF4
specific antibodies. (B) The reverse experiment was also performed where ATF4 antibodies
were used to precipitate the endogenous protein complex and GFP antibodies were then used
to identify any GFP-Abro1 protein bound to ATF4. (C) HEK293T cells were plated in duplicate
on glass-cover slips and co-transfected with GFP-Abro1 and mRFP-ATF4. Half of the
transfected cells were treated with tunicamycin and the other half used as control. Cells were
stained with DAPI nuclear staining and visualized using a confocal microscope system. White
arrows indicate cells that show co-localization of GFP-Abro1 with mRFP-ATF4 in the cell
nucleus. (D) Three-hundred cells were counted in total between 15 different fields of view. Cotransfected cells were categorized as having GFP-Abro1 in the cytoplasm or nucleus. A
percentage of the total counted cells is represented here. (E) HEK293T cells were grown and
either left untreated for control, treated with tunicamycin or H2O2. Cells were then collected and
nuclear/cytoplasmic fractionation was carried out, followed by analysis through SDS-PAGE and
Western blot using ATF4 or Abro1 specific antibodies. β-actin and Histone H1 antibodies were
used as cytoplasmic and nuclear markers respectively. *, p < 0.05 versus cytoplasmic control.
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Figure 9. Regulation of ATF4 and Abro1 protein levels by tunicamycin.
HEK293T cells were treated with various concentrations of tunicamycin. Total cell lysates were
collected and analyzed by SDS-PAGE and Western blotting using ATF4 (A) or Abro1 (B)
specific antibodies. β-actin was used to verify equal loading of proteins in each lane. Lower
panels show ATF4/β-actin or Abro1/β-actin ratio calculated after densitometry analysis.
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Figure 10. ATF4 is required for Abro1-mediated cytoprotection during oxidative stress.
HEK293T cells were co-transfected in duplicate with GFP-Abro1 or GFP-vector alone as well as
with control siRNA (siCON) or ATF specific siRNA (siATF4). Half of the cells were treated with
H2O2 to induce oxidative stress and cell death. (A) The percentage of apoptotic cells in the
population was monitored by Annexin V staining and FACS. (B) Western blot analysis of the
endogenous ATF4 protein level; bottom panel shows ATF4/β-actin ratio calculated after
densitometry analysis. β-actin was used to verify equal loading of proteins in each lane.
Results shown are means ± S.D. of three independent experiments. (C) Western blot analysis
for the endogenous level of Abro1 as well as GFP-Abro1 proteins in the samples used for (A).
*, p < 0.05 versus GFP-vector; ‡, p < 0.05 versus GFP-Abro1 siCON + H2O2.
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Figure 11. Schematic diagram showing the current composition of the BRISC and
BRCA1-A DUB complexes.
Both BRISC and BRCA1-A complexes share three common subunits (BRCC36, BRE,
MERIT40) that compose the catalytic core. BRCA1-A complex contains two unique proteins,
RAP80 and the BRCA1-BARD1 heterodimer, that are used to target the complex. Our work
also identified four unique proteins (THAP5, ATF4, ATF5 or JunD), three of which are members
of the AP-1 family, which can be used to target the BRISC complex to the cell nucleus under
conditions of cellular stress.
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CHAPTER 3: MULAN E3 UBIQUITIN LIGASE IS INVOLVED IN
MULTIPLE PROTEIN-PROTEIN INTERACTIONS AND PARTICIPATES
IN MITOPHAGY BY RECRUITING GABARAP
Introduction
Autophagy is generally believed to be a process in which nonspecific degradation
of cytoplasmic content, including organelles, occurs (87). Recent studies have revealed
that there is specificity in autophagy that allows the degradation of specific cargo. Such
selective types of autophagy include mitophagy, the process whereby damaged
mitochondria are removed from the cell (109). Mitophagy is crucial for many
physiological processes such as development and differentiation, and its deregulation
has been implicated in Parkinson’s disease, as well as various infections and cancers
(86, 87). Mitophagy has been shown to be mediated by the E3 ubiquitin ligase parkin,
which is recruited to the mitochondria by PINK1 (PTEN-induced putative kinase protein
1). Recent studies have identified yet another mitochondrial E3 ubiquitin ligase,
Mulan/Hades/GIDE (mitochondrial ubiquitin ligase activator of NF-κB; hereafter referred
to as Mulan) to play a role in mitophagy (123, 151). We have identified Mulan as a
specific substrate of the mitochondrial Omi/HtrA2 protease. Furthermore, inactivation of
Omi/HtrA2 protease leads to the accumulation of Mulan protein and increased
mitophagy (123).
Mulan is one of three E3 ubiquitin ligases that are present in the mitochondria,
the other two being MARCH5/MITOL (membrane associated RING-CH5) and RNF185
(152, 153). Mulan is a 352-residue polypeptide that crosses the mitochondria outer
membrane (OMM) twice, positioning its amino-terminus - which includes the RING
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finger domain - to the cytoplasm and forming a large domain in the inter-membrane
space (IMS) of the mitochondria (Figure 11A). Both the mitochondrial localization signal,
as well as an intact RING finger domain have been shown to be necessary for Mulan’s
function (154). Mulan’s location suggests that its substrates will be proteins that are
either integral or associated with the mitochondria, and whose function can be affected
by ubiquitination.

Mulan has been shown to directly or indirectly regulate various

proteins including NF-κB, JNK, p53, Akt and Mfn2, which suggest that it plays a role in
cell growth as well as apoptosis (151, 154-158). In order to investigate the mechanism
by which Mulan participates in mitophagy, we set out to identify E2 ubiquitin conjugating
enzymes that form specific complexes with Mulan (151). We used the cytoplasmic
domain of Mulan (amino acids 259-352) that includes its RING finger domain, and
identified four E2 conjugating enzymes, namely Ube2E2, Ube2E3, Ube2G2 and
Ube2L3, as specific interactors. We then used fusion baits consisting of Mulan’s RING
finger domain attached to the full length of each of the four specific E2’s that were
identified. These fused baits were used to screen for possible substrates of the
heterodimer Mulan-E2 complex.

In this screening, several distinct interactors were

identified for each of the four Mulan-E2 complexes.
One of the isolated heterodimer interacting proteins was GABARAP (GABAA
receptor-associated protein), a known member of the Atg8 that includes LC3 (also
known as MAP1LC3). The proteins of the Atg8 family are integral players in
autophagy/mitophagy, (159), and are part of the ubiquitin-like conjugating cascade.
They share similarities, including their interacting motif which is essential for selective
autophagy, however each Atg8 protein also has many distinct features (160, 161).
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GABARAP is known to bind to many different proteins and it plays a role in the
elongation of the autophagosome (162, 163). Our data show that the interaction of
GABARAP requires the presence of Ube2E3 as well as a specific amino acid motif
located in the RING finger domain of Mulan. This motif is known as LC3-interacting
region (LIR) motif, and is present in other proteins that interact with LC3 and/or
GABARAP (101, 162, 164, 165). The consensus for the LIR motif is (W/F/Y)xx(L/I/V)
(166). Our present study characterized the mechanism of Mulan’s function in mitophagy
as the recruiter of GABARAP. Mulan interacts with GABARAP but not LC3B, suggesting
that this interaction is involved in the same pathway but operates downstream of
PINK1/parkin/LC3.

Materials
Yeast Two-Hybrid Screening of Mulan Interactors
The EGY 48 yeast strain with the LexA-β galactosidase reporter construct (PSH
18–34) was used to perform a yeast two-hybrid screen on a mouse embryonic cDNA
library as previously described (32, 46, 47). The bait used was the cytosolic carboxyterminus sequence of the Mulan protein (amino acids 259-352) cloned in the pGilda
vector (Clontech) and expressed as a LexA fusion protein. Both a mouse embryonic
and a HeLa cDNA library were used. Several interacting proteins were identified in this
screen, including cDNAs for Ube2E2, Ube2E3, Ube2G2 and Ube2L3 (a complete list of
the interactors found is summarized in Table 2). To clone the full-length cDNA, primers
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were designed with an MfeI/EcoRI site at the 5′ end and XhoI site at the 3′ end. PCR
products were digested and cloned in frame into the prey pJG4-5 vector.

Yeast Two-Hybrid Screening of Mulan-E2 Fusion Interactors
To make the hybrid fusion proteins, primers were designed with the addition of a
five amino acid linker (Gly-Gly-Ser-Gly-Gly) as previously described (Table 4) (167).
These primers contained the last 21 nucleotides of the Mulan protein and the first 16
nucleotides of the specific E2 flanking the linker sequence. After the first PCR reaction
the products for Mulan259-352 and the full-length E2 conjugating enzyme were isolated,
gel purification, and added together as the template for the second PCR reaction
(Figure 12A). The resulting product of the PCR was MfeI/EcoRI-Mulan259-352-G-G-S-GG-Specific E2-XhoI. The product was then digested using MfeI/EcoRI and XhoI and
cloned in frame into the bait pGilda vector. The LexA-fusion proteins were then used as
the bait in the screening of a HeLa cDNA library. The presence and stability of the
recombinant proteins in yeast cells was monitored by Western blot analysis using LexAantibodies (for baits) or HA-antibodies (for preys).

Cell Culture
HEK293T cells were grown in DMEM supplemented with 10% fetal calf serum
(Atlanta Biologicals), 2mM L-glutamine, 1.5g/l sodium bicarbonate, 1mM sodium
pyruvate, 50U/ml penicillin, and 50µg/ml streptomycin (Invitrogen) at 37°C and 5% CO2.
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Interaction Between Mulan and GABARAP Proteins in HEK293T Cells
HEK293T cells were plated in 100mm dishes and transfected with 8.0µg of total
DNA between EGFP-GABARAP and either mRFP-Mulan (amino acids 1-352) plasmid
or mRFP-C1 empty vector (Clontech) using Lipofectamine 2000 reagent according to
the manufacturer’s instructions (Invitrogen). Fourteen hours after transfection, one plate
was treated with 2µM MG132 for 10 hours and the other half were used as control
(untreated). Cell lysates were prepared in RIPA buffer (150mM NaCl, 50mM Tris-HCl
pH 7.5, 1% NP-40, 0.25% sodium deoxycholate) containing the protease-inhibitor
cocktail (Roche). The lysates were cleared by centrifugation for 10 min at 10000g, and
total lysates were collected and subjected to immunoprecipitation.

Approximately

200µg of total protein cell lysate was pre-cleared by mixing with protein G-Agarose
beads (Roche) for 1 hour followed by incubation with GFP (Santa Cruz Biotechnology)
polyclonal antibodies for 2 hours at 4C. Protein G-Agarose beads were then added
and allowed to bind overnight at 4C.

Immunoprecipitates were collected by brief

centrifugation for 3 min at 800g and washed three times with 500µl RIPA buffer. After
the final wash, 25µl of RIPA buffer and 25µl of 2X SDS-PAGE sample buffer were
added. All procedures were performed at 4°C. Samples were boiled for 5 min and
resolved by SDS-PAGE.

Proteins were then electro-transferred onto a PVDF

membrane and probed with either a rabbit polyclonal Mulan (Novus Biologicals),
followed by a Rabbit TrueBlot (eBiosciences) HRP-conjugated secondary-antibodies.
The immunocomplex was visualized using a SuperSignal West Pico Chemiluminescent
Substrate (Pierce).
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LIR-motif Studies
Two amino-acids found in the LIR-like motif of Mulan were mutated, specifically
Tyr327Ala and Leu330Ala. To achieve this, two primers were designed where the
codons were changed to encode for the Alanine. The LexA-Mulan259-352-Ube2E3 was
used as the template for the first PCR reaction, where the primers were paired with the
LexA forward or reverse primer. In the second round of PCR, a small amount of each
product was used as the template along with external primers creating restriction sites.
The PCR product was purified and digested with MfeI and XhoI, then cloned in frame in
pGilda vector as described above. Single colonies were selected and sent for
sequencing to verify the mutation. Expression of the mutant protein was also verified
with Western blot analysis using the LexA-antibody.

Results

Isolation of Mulan259-352 E2 interactors
Mulan is a mitochondrial E3 ligase which contains two transmembrane domains,
an inter-membrane domain as well as a short cytosolic amino-terminus and a longer
carboxy-terminus where the RING domain that is necessary for its function is located
(Figure 11A) (154, 155). This cytosolic domain was cloned in-frame in the pGilda vector
and expressed as a LexA-Mulan259-352 fusion protein that used in a yeast two-hybrid
screening. Both a mouse embryonic and a HeLa cDNA library were used and four
specific interactors were isolated. All four are members of the E2 conjugating enzyme
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family (Table 2) and include the Class I Ube2G2 and Ube2L3 as well as the Class III
Ube2E2 and Ube2E3 (Figure 11B).

Creating the Mulan259-352-E2 Fusion Bait & Isolation of Substrates
For ubiquitination to occur, the E3 ligase must interact with an E2 conjugating
enzyme that provides the substrate specificity. E3 ligases are subdivided into five large
families according to the presence of E3 signature motifs: HECT, RING, U-box, PHD
and LAP (168). RING family ligases, such as Mulan, act as a scaffold that bring the
E2~Ub in proximity of the substrate for the direct transfer of the active ubiquitin (169).
Based on this information, we used a modified yeast two-hybrid system (167) to find
specific ubiquitination substrates for each of the Mulan-E2 heterodimer complexes.
We created fusion bait proteins where the cytosolic portion of Mulan with the
RING domain was fused to one of the four isolated E2 conjugating enzymes using a five
amino acid linker (Figure 12A). Expression and stability of each LexA-Mulan259-352-E2
bait was tested by Western blotting using anti-LexA antibodies (Figure 12B). Fused
baits were then used to screen a HeLa cDNA library and the results from these
experiments are shown in Table 3.

Isolation of Mulan259-352-Ube2E3 Substrates
We used the LexA-Mulan259-352-Ube2E3 fusion bait to screen a HeLa cDNA
library. During the screening, we isolated four novel interactors of the heterodimer:
GABARAP (GABAA receptor-associated protein), GRP78 (also known as Hsp5a and
immunoglobulin heavy chain-binding protein (BiP)), as well as two members of the
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Class I E2 conjugating enzyme family, Ube2D2 and Ube2D3 (Table 3). Ube2D2 and
Ube2D3 are members of the Ubch5 family, known as initiation E2 enzymes. These
enzymes are important in the addition of the first ubiquitin; they do not play a role in
ubiquitin chain elongation (170). It has been shown that E3 ligases can interact with
multiple E2 enzymes which can explain this interaction (171). The protein GRP78 is an
ER chaperone that has been shown to localize in the cytosol and ER membrane in cells
undergoing ER stress where it can interact with caspase-7, -12 and other cytosolic
proteins (172). When cells are stressed due to the unfolded protein response (UPR),
GRP78 translocates into the mitochondria, where Mulan is located. (173). The
GABARAP protein is a member of the Atg8 family and has been linked to autophagy
(174). Since Mulan has also been recently linked to mitophagy, we were very interested
to further investigate this interaction (151). The isolated clone of GABARAP
encompassed amino acids 36-417, lacking the amino-terminus. To test if the interaction
would still occur with the full-length protein, we cloned GABARAP1-417 into the pGJ4-5
prey vector and monitored the interaction with the fusion protein. The full-length protein
was unable to interact with the fusion bait (data not shown); however, we continued to
use this as a substrate of the complex because previous researchers have encountered
the same problem when using the full-length GABARAP in yeast two-hybrid screenings
but were successful in seeing interaction of the proteins in mammalian cells (175).

Heterodimer Interaction Specificity
To investigate if the interaction between GABARAP and GRP78 was specific to
the heterodimer Mulan259-352-Ube2E3 complex, and not to the individual proteins, we
50

cloned Ube2E3 full-length in frame in the pGilda vector and used the LexA-Ube2E3,
LexA-Mulan259-352 as well as the fusion LexA-Mulan259-352-UbeE2E3 as baits. There was
no interaction between the single bait proteins and the identified substrates, suggesting
this interaction is specific for the Mulan-Ube2E3 heterodimer (Figure 13A).

Isolation of Mulan259-352-Ube2E2 Substrates
A yeast two-hybrid screening of a HeLa cDNA library was carried out using the
LexA-Mulan259-352-Ube2E2 as bait and the following possible substrates were isolated:
RNF61/MKRN1, RNF103 and RNF14/ARA54. RNF14 and RNF103 proteins are known
interactors of Ube2E2 (176, 177) (Figure 13C). RNF14’s RING domain was shown to
interact with the UBC domain of Ube2E2 both in vitro and in vivo, while RNF103 was
shown to bind Ube2E2 in a yeast two-hybrid system (176, 177). None of the three
interactors bound to LexA-Mulan259-352. Since the interaction was mediated by the E2
and not by Mulan-E2 heterodimer, RNF14 and RNF103, were not further studied. The
third protein isolated as an interactor of LexA-Mulan259-352-Ube2E2 was RNF61, also
known as Makorin ring finger protein 1 (MKRN1) and it is expressed ubiquitously from
fetus to adulthood (178). MKRN1 contains a RING finger domain which gives it the E3
ubiquitin function and it substrates include p53 and p21, both important proteins
involved in cell cycle and apoptosis (179). Its interaction with p53 leads to a p53depenedent cell death pathway by suppressing p21 (179).
E3 conjugating enzymes Ube2E2 and Ube2E3 have very similar amino acid
sequence (Figure 13D) so we verified that the interaction of LexA-Mulan259-352-Ube2E3
with GABARAP as well as GRP78 was specific. Both GABARAP and GRP78 did not
51

interact with LexA-Mulan259-352-Ube2E2 (Figure 13E), illustrating the specificity of the
heterodimer complex.

Isolation of Mulan259-352-Ube2L3 and Mulan259-352-Ube2G2 Substrates
Next, we used the fusion bait LexA-Mulan259-353-Ube2L3 to screen the HeLa
cDNA library. We found ARIH2/TRIAD1, an E3 ligase, to interact with our fusion bait
(Figure 13B). This protein also interacted with LexA-Ube2L3 bait. ARIH2/TRIAD1 is
known to interact with one of the two RING domains of Ube2L3 (180). Due to this
information, we did not proceed into mammalian studies with this protein. Lastly, we
were unable to screen the HeLa cDNA library with the LexA-Mulan259-353-Ube2G2 fusion
bait due to self-activation. For a complete list of all interectors isolated refer to Table 3.

LIR-like Motif Specificity
It has been well documented that proteins which act as mediators between
ubiquitinated proteins and LC3 and/or GABARAP, such as p62, contain a linear motif
with the core consensus (W/F/Y)xx(L/I/V) (101, 166, 181). We found Mulan to contain
the characteristic LC3-interacting region (LIR) at Y(327)xxL(330) in the amino-terminus
which is exposed to the cytosol (Figures 14A and 14B). Unlike other autophagic adapter
proteins, Mulan’s physiological location in the OMM bypasses the need for
ubiquitination to help deliver the damaged mitochondrion to the autophagosome. To
demonstrate that the interaction between the heterodimer Mulan 259-352-Ube2E3 and
GABARAP is through this motif, we generated a mutant at amino acids Y327A and
L330A. When the mutant LexA-Mulan259-352MUT-Ube2E3 was used as the bait, we did
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not see any interaction with the GABARAP protein (Figure 14C). This data
demonstrates that the interaction between Mulan and GABARAP is LIR specific. To
further show that the interaction is specific to GABARAP and not the Atg8 family
members, we used LC3B as a prey. There are four isoforms of LC3, with LC3B being
the only one that is induced during vacuolation (182). LC3B did not interact with the
LexA-Mulan259-352-Ube2E3 heterodimer or the mutant form, once again showing
specificity of the GABARAP interaction.

Discussion
Mulan’s function has been linked to organelle dynamics, apoptosis, mitochondrial
fission and mitophagy, through its interaction with NF-κB, JNK, p53, Akt and Mfn2 (154156). Mulan is an E3 ubiquiting ligase and needs to interact with a conjugating E2
enzyme in order to carry out its function. The identity of these E2 conjugating enzyme(s)
is unknown.

In this paper we identify the conjugating E2 enzymes that interact

specifically with Mulan. Furthermore, we used a modified yeast two-hybrid system in
which the Mulan-E2 heterodimer was a bait to identify specific substrates for each
complex. Specificity of substrates is due to the heterodimer formed between the E3 (in
this case Mulan) and E2. GABARAP was one of the proteins isolated during the
screening for substrates of Mulan-Ube2E3.
The bulk degradation of cytosolic material by autophagy was believed to be
nonspecific, but recent data suggests that there is specificity to this process through the
identification of target proteins (96). Several proteins important in ubiquitination have
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been linked to targeted autophagy, which is a beginning to understanding the crosstalk
between proteasomal and autophagy degradation (183). Mulan functions as an E3
ubiquitin ligase and is found in the outer mitochondrial membrane, where its RING
finger domain is facing the cytosol and can interact with E2 conjugating enzymes as
well as substrates (155). Many E3 ligases are part of a multi-subunit heteromeric
complex which generally includes an E2, adaptor proteins, and the substrate. They
could also contain anchor proteins for a particular compartment as well as regulatory
proteins (76). Previously, there were no known E2 interactors of Mulan identified; in this
report we were able to isolate the Class I Ube2G2 and Ube2L2 as well as the Class III
Ube2E2 and Ube2E3 as interactors of Mulan. The E2s are classified according to the
addition of an extension at the amino-terminus and/or carboxy-terminus to the catalytic
core UBC domain. Class I E2s consist of only the catalytic domain, Class II and Class III
have the extension at either the amino- or carboxy-terminus respectively, and Class IV
have both extensions (64). There are also different classes of E3 ubiquitin ligases
including the RING family of which Mulan is a part of. RING-type E3s act as scaffold
proteins, bringing the E2 and substrate in close proximity for the transfer of the ubiquitin
directly from the E2 to the substrate (184).
Since the interaction between the E2 and E3 are very weak and transient, many
groups have used high throughput screening to identify novel interactions between E2
and E3s, (167, 185, 186). In our work, a yeast two-hybrid system was used to isolate E2
interactors of Mulan. We were able to identify eight total novel substrates of Mulan by
using this technique (Table 3). Isolated substrates can be divided into those that were
only able to interact with the complete heterodimer or those that interacted with both the
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heterodimer and the specific E2. Of the isolated interactors, three are previously known
interactors of the specific E2 being used, providing evidence that the screening was
successful. The multiple complexes formed between Mulan and the various E2s sheds
light on how the specific recruitment of the E2 determines the function and the
substrates of Mulan. In addition, Mulan-E2 fusion baits were used to identify specific
interactors of the heterodimer complex. One of these interactors was GABARAP, a
protein that has been linked to autophagy, which suggests the mechanism of Mulan’s
function in this process. GABARAP is a ubiquitously expressed protein that was
originally isolated as an interactor of the GABAA receptor. GABARAP can also interact
with the cytoskeleton, emphasizing the role of this protein in the reuptake of the GABAA
receptor. It was also noted that the GABARAP protein contained similarities to the LC3,
a component of the MAP complex important in autophagy (175, 187).
Autophagy occurs when a double-membrane vesicle (autophagosome) is formed
around unwanted content in the cell, such as damaged organelles or protein aggregates
(188). The vesicle is then delivered to the lysosome, where the content is degraded and
the product is recycled as nutrients (100). Mitophagy is the process where damaged
mitochondria are removed from the cell. In addition to supplying energy to the cell,
mitochondria are also a major source of reactive oxygen species (ROS) (102). The
removal of excess or damaged mitochondrion then becomes an essential process to
protect the cell from damage. Defects in the autophagy progress can cause the
accumulation of ubiquitinated proteins leading to neurodegeneration (189, 190).
Omi/HtrA2 is a serine protease with high homology to the bacterial HtrA endoprotease,
a protein with proteolytic activity which removes damaged and misfolded proteins at
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high temperatures (32). The mature form of Omi/HtrA2 is found in the IMS of the
mitochondria, but it is released to the cytosol under cellular stress where it can
participate in caspase-dependent and caspase-independent apoptosis pathways (31).
While in the IMS, Omi/HtrA2 has been implicated in pro-survival functions. Mice lacking
the active form of the protease (known as mnd2 mice) show a Parkinsonian phenotype
and die within 30 days after birth (40). Furthermore, mice lacking Omi/HtrA2 function in
non-neuronal tissues are observed to undergo premature aging (191). Omi/HtrA2 thus
seems to play an important role in cell survival. Recently, lack of functional Omi/HtrA2
was linked to loss of functional mitochondria as well as an increase in Mulan protein
level (123). The IMD of Mulan can be degraded by Omi/HtrA2 in vitro (5).
Parkin, which is also an E3 ligase, participates in mitophagy is recruited to
mitochondria by PINK1 (192). Parkin then ubiquitinates mitochondrial proteins such as
p62/SQSTM1 which act as an adapter and through the specific LIR-motif interact with
members of the Atg8 family, such as LC3 (120). This interaction allows for the formation
of the phagophore around the damaged mitochondrion, giving it specificity for the
content of the vacuole (165, 193). The LIR-like motif is also found in Mulan (amino
acids 327-330), which we show to be responsible for the interaction between Mulan and
GABARAP. Furthermore, we show that this interaction between GABARAP and MulanUbe2E3 is specific; since when the highly homologous Ube2E2 enzyme was used, the
complex was unable to interact with LC3B. In our present study we characterized the
mechanism of Mulan’s function in mitophagy as the recruiter of GABARAP. GABARAP
participates in the formation of the autophagosome at a different time point than
PINK1/parkin/LC3. Mulan interacts with GABARAP but not LC3, suggesting that this
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operates

downstream

of

Table 2. A list of the four E2 that were isolated through the yeast two-hybrid screen as
Mulan259-352 specific interactors.

Mulan259-352 Interactors

Accession Number

Ube2E2

NM_152653

Ube2E3

NM_006357

Ube2G2

NM_019803

Ube2L3

NM_003347

Table 3. A list of Mulan259-352-E2 fusion interactors isolated in our yeast two-hybrid screen
using a HeLa cDNA library. (*) denotes previously identified interactors of the
corresponding E2.

Mulan259-352-Ube2E3
Interactors

Accession Number

GABARAP

NM_007278

GRP78

NM_005347

Ube2D2

NM_003339

Ube2D3

NM_181891

Mulan259-352-Ube2E2
Interactors

Accession Number

RNF103 *

NM_001198951

RNF14

NM_183401

RNF114 *

NM_018683

Mulan259-352-Ube2L3
Interactors

Accession Number

ARIH2 *

NM_006321
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Table 4. A list of the primers used to create the LexA-Mulan259-352-Specific E2, LexASpecific E2 fusion baits, LexA-Mulan259-352 and LexA-Mulan259-352(MUT). Underlined is the
linker sequence, in italics is the restriction enzyme site and in bold is the mutated
nucleotide.

Primer Name

Restriction
Enzyme

Ube2E3 Fusion Fw

-

Ube2E3 Fusion Rv

-

Ube2E3 Fw

MfeI

GCG CAATTG ATGTCCAGTGATAGGCAAAGG

Ube2E3 Rv

XhoI

CTG CTCGAG TTATGTTGCGTATCTCTTGGTCCAC

Ube2E2 Fusion Fw

-

Ube2E2 Fusion Rv

-

Ube2E2 Fw

MfeI

GCG CAATTG ATGTCCACTGAGGCACAAAG

Ube2E2 Rv

XhoI

CCG CTCGAG CTATGTGGCGTACCGCTTG

Ube2G2 Fusion Fw

-

Ube2G2 Fusion Rv

-

Ube2G2 Fw

EcoRI

GCG GAATTC ATGGCGGGGACCGCGCTC

Ube2G2 Rv

XhoI

CTG CTCGAG TCACAGTCCCAGAGACTTCTG

Ube2L3 Fusion Fw

-

Ube2L3 Fusion Rv

-

Ube2L3 Fw

EcoRI

GCG GAATTC ATGGCGGCCAGCAGGAGGCTG

Ube2L3 Rv

XhoI

CCG CTCGAG TTAGTCCACAGGTCGCTTTTCC

Mulan259-352 Fw

MfeI

GCG CAATTG CGGAAGCAGTATCTGCAGCG

Mulan259-352 Rv

SalI

CTCC GTCGAC TTAGCTGTTGTACAGGGGTATCA

-

GCACCGAGTGC GCCCGCGCCGCG CCAGAGCCC

-

GGGCTCTGG CGCGGCGCGGGC GCACTCGG

Mulan259-352(MUT)
Fw
Mulan259-352(MUT)
Rv

Sequence
ACCCCTGTACAACAGC GGTGGTTCCGGTGGT
ATGTCCAGTGATAGGCAAAGG
CCTTTGCCTATCACTGGACAT ACCACCGGAACCACC
GCTGTTGTACAGGGGTATCAC

ACCCCTGTACAACAGC GGTGGTTCCGGTGGT
ATGTCCACTGAGGCACAAAG
CTCTTTGTGCCTCAGTGGACAT ACCACCGGAACCACC
GCTGTTGTACAGGGGTATCAC

ACCCCTGTACAACAGC GGTGGTTCCGGTGGT
ATGGCGGGGACCGCGCTCAAGAAGC
CTTGACCGCGGTCCCCGCCAT ACCACCGGAACCACC
GCTGTTGTACAGGGGTATCAC

ACCCCTGTACAACAGC GGTGGTTCCGGTGGT
ATGGCGGCCAGCAGGAGGCTG
CAGCCTCCTGCTGGCCGCCAT ACCACCGGAACCACC
GCTGTTGTACAGGGGTATCAC
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Figure 12. Mulan’s RING finger domain interacts with E2 conjugating enzymes found in
the cytoplasm.
(A) Schematic diagram of the Mulan protein E3 ligase and its topology in mitochondria. Mulan is
a 352-residue protein with two transmembrane domains (TMD ), an intermembrane space
domain as well as a short cytosolic amino-terminus and a longer carboxy-terminus where the
RING domain (RNF ) is located. The cytosolic carboxy-terminus was used as the bait in a
yeast two-hybrid screen. (B) Interaction of four specific E2 conjugating enzymes with LexAMulan259-352 isolated in the yeast two-hybrid screening. Blue yeast colonies result from a positive
protein-protein interaction between the bait and prey.
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Figure 13. Fusion baits used during a modified yeast two-hybrid screening.
(A) Schematic representation of the method used to create the LexA-Mulan259-352-E2 fusion
baits. More information can be found in the Methods section. (B) Expression and stability of the
various recombinant fusion baits used in the yeast two-hybrid screening. Single yeast colonies
were grown overnight, induced with galactose/raffinose media the next day for four hours and
then used in a Western blot analysis.
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Figure 14. Specificity of interaction between isolated preys with different fusion bait
proteins.
(A) Specificity of interaction between isolated preys with different fusion bait proteins. The
interaction of GABARAP and GRP78 was only present when Mulan and Ube2E3 were
expressed together. (B) The fusion bait was used in a screening. Interaction of ARIH2 with the
heterodimer is through Ube2L3. (C) The fusion bait was used in a screening. The interaction of
RNF103 and RNF114 is through UbeE2. RNF14’s interaction is specific to the heterodimer. (D)
Alignment of the amino acid sequences of Ube2E2 and Ube2E3 used in our experiments to
illustrate their similarities. [MultAlin software (http://multalin.toulouse.inra.fr/multalin)]. (E) To
further characterize interaction specificity both fusion baits Mulan 259-352-Ube2E2 and Mulan259352-Ube2E3 were used. Both GABARAP and GRP78 only interacted with Mulan 259-352-Ube2E3
and not the highly homologous Mulan259-352-Ube2E2.
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Figure 15. LIR motif of Mulan is necessary for the interaction with GABARAP.
(A) Comparison of typical LIR motif present in proteins that interact with the Atg8 family
members, which is also found in Mulan. The highlighted amino acids indicate the conserved
residues of the LIR in all proteins shown. (B) Schematic representation of the Mulan protein in
the mitochondria outer membrane, along with the location of the putative LIR. (C) Specificity of
interaction between the Atg8 family members GABARAP and LC3 with the Mulan259-352-Ube2E3
heterodimer and LIR mutant. By mutating the conserved residues to Alanine the interaction with
GABARAP is lost. (D) Expression of both the Mulan259-352-Ube2E3 wild type and LIR mutant in
yeast. (E) Expression the preys, GABARAP-HA and LC3B-HA.
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CHAPTER 4: CONCLUSION
Omi/HtrA2 is a serine protease with a well-documented function in apoptosis.
Recent genetic studies suggest it might have a secondary function as a regulator of
mitochondrial homeostasis (31, 40). In the preceding chapters we described a new
approach used to elucidate the cytoprotective function of Omi/HtrA2. The study of this
mitochondrial protease has been the focus of our studies for the past ten years.
Omi/HtrA2 was originally isolated in our lab and since then we have developed many
tools for studying it, including a specific inhibitor (ucf-101), and identified Hax-1, THAP5,
and Mulan as specific interactors and substrates of the protease (31, 46, 47, 123).
We have recently characterized Abro1 as a protein that is modulated following
myocardial ischemia/reperfusion (MI/R) injury, where the protein levels are increased
and provide cytoprotection.

Abro1 is a novel scaffold protein, part of the BRISC

complex that plays a role in Lys63-deubiquitination (126, 129). This protein was
identified as a specific interactor of THAP5, a transcription factor isolated in our lab as a
substrate of Omi/HtrA2 (194). Abro1 is closely related to another protein, Abraxas,
which is also a scaffold protein in the deubiquitinating (DUB) complex known as BRCA1
(125-127, 130). The unique carboxy-termini of these two scaffold proteins give them
their distinct functions (131). To further understand the mechanism of Abro1 in
cytoprotection, we used the unique carboxy-terminus of Abro1 as a bait in a yeast twohybrid screen, and isolated three members of the AP-1 family: ATF4, ATF5 and JunD.
These transcription factors are important in cell growth, regulation, and cell cycle control

64

(133). We further characterized this interaction to be unique to Abro1 and restricted to
only these three members of the very large AP-1 family.
The BRISC complex has a similar composition to BRCA-1, another DUB complex
(126, 127). The two complexes share three proteins in common: BRCC36, BRE and
MERIT40 (126, 127). These proteins interact with the highly homologous aminoterminus of Abro1 and Abraxas. BRCA-1 is known to act on damaged double stranded
DNA; however, little is known about the function of the BRISC complex (125, 126, 132).
BRCA-1 is recruited to DNA damage sites through the interaction of its RAP80 subunit
with ubiquitinated histones (125, 131). The BRISC complex does not contain the RAP80
protein; however, we hypothesized that THAP5 or the isolated AP-1 family members
(ATF4, ATF5, and JunD) could function in a similar manner to drive the complex to
various subcellular locations. Overexpression of Abro1 provides cytoprotection, but only
in the presence of ATF4. Under these conditions, cytoplasmic Abro1 was translocated
to the nucleus with the help of the transcription factor ATF4. These findings provide new
information on the mechanism of cytoprotection by Abro1 and its indirect regulation by
Omi/HtrA2 protease.
To further characterize the cytoprotective function of Omi/HtrA2 within the
mitochondria, we studied the expression of the three known mitochondrial E3 ubiquitin
ligases: Mulan, MARCH5/MITOL and RNF185 (152, 153, 155). We found that the IMS
domain of Mulan can be cleaved by Omi/HtrA2 in vitro (123). In animal models that lack
the Omi/HtrA2 protein or carry an inactive protease, there is accumulation in Mulan
protein level as well as increased mitophagy (123). For an E3 ligase to perform its
function, it needs to interact with an E2 ubiquitin conjugating enzyme (2). Since Mulan is
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a RING protein, the RING domain was used to isolate and identify these E2s (195). In
these studies, we isolated four distinct E2s as specific interactors of Mulan. These
included the class I E2 conjugating enzyme members Ube2G2 and Ube2L3 as well as
the class III E2 conjugating enzymes Ube2E2 and Ube2E3 (64, 171, 185, 186). The
different E2s suggest Mulan can have multiple functions depending on the nature of its
interacting E2 partner. To further characterize its function, we searched for substrates of
Mulan when associated with a specific E2. Specifically, a fusion bait protein was
generated where the Mulan RING domain was joined to the full length specific E2 using
a small five-amino acid linker. This approach allowed us to screen for proteins that
interact with the Mulan-E2 fusion but not with the individual Mulan or E2 proteins alone.
Unique proteins to each heterodimer complex were isolated, and since our interest is
mitophagy, we focused on the interaction between Mulan-Ube2E3 and GABARAP.
We characterized the interaction of Mulan with GABARAP both in vitro and in
vivo. These studies showed that Mulan’s cytosolic portion contains an LIR motif that is
necessary for its interaction with GABARAP. This interaction is similar to the one
identified between the mitochondrial protein PINK1, the cytosolic E3 ligase parkin, and
the Atg8 family member LC3, which leads to selective mitophagy (113, 115-117, 196,
197). LC3 and GABARAP are members of the same family of proteins and interact with
phosphoethanolamine (PE) in phagophores (124, 159, 160, 198, 199). Adaptor proteins
which can bind Atg8 family members have been identified, allowing for selectivity in the
content of the phagosome (94, 101, 105, 115, 200-202). These adaptor proteins all
share a similar LIR motif (166). The PINK1/parkin/LC3 process is initiated in
mitochondria that are damaged or have lost their mitochondrial potential due to cellular
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stress (109, 111-117). When mitochondria are damaged beyond repair, they undergo
fission followed by mitophagy (104, 153, 203). Our proposed pathway of MulanUbe2E3/GABARAP may work in conjunction with the PINK1/parkin/LC3 pathway or in a
later stage of the phagophore formation. There have been reports that the GABARAP
protein increases at the time in which the vesicle is being closed (124, 159).
Additionally, the PINK1/parkin/LC3 mitophagy-pathway in vivo is only seen when there
is a catastrophic mitochondrial dysfunction and not as a response to the gradual
accumulation of damaged mitochondria (197). This could explain the unique role of the
Mulan-Ube2E3/GABARAP pathway but further studies are necessary to verify and
expand our results.
The discovery and identification of Mulan as a participant and possibly a major
player in mitophagy may help explain in part the role of Omi/HtrA2 as a pro-survival
protein while in the mitochondria (53, 204). In cells that have damaged mitochondria,
Omi/HtrA2 does not cleave Mulan, which leads to the accumulation of this protein and
increased mitophagy (123). A physiological characteristic of PD patients is the
accumulation of damaged mitochondria, which is also seen during normal aging (205).
Animals that lack the Omi/HtrA2 protein or carry an inactive protease develop motor
neuron disease with a parkinsonian phenotype, premature aging and a shortened
lifespan (40, 191). The contribution of Mulan in these processes and whether other
mitochondrial proteins are involved is unclear. We expect that mitochondrial damage
and deregulated mitophagy are involved, and that Omi/HtrA2 protease plays a central
role in this process. In addition, whether any human disorders similar to those observed
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in Omi/HtrA2 KO animals are caused by the inactivation or deregulation of the Mulanmitophagy pathway remains to be elucidated.
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APPENDIX: COPYRIGHT
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